Gene editing and gender-specific medicine: a challenge for dementia research

被引:0
作者
Silvia Zullo
Luciana Caenazzo
机构
[1] University of Bologna,Department of Legal Studies
[2] University of Padua,Department of Molecular Medicine
来源
Palgrave Communications | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Gender-specific medicine is a clinical discipline that studies the impact of sex and gender on physiology, pathophysiology, and diseases. Human genome modification of somatic cells could be useful for treating or preventing a range of diseases and for improving the safety and efficiency of existing gene therapy techniques currently in use or under development for clinical application. Sex and gender differences have been analysed in the incidence and prevalence of dementia. In fact, epidemiological studies have demonstrated that women are at a higher risk than men for developing dementia or Alzheimer’s disease (AD); however, the reasons for these differences are not completely known, and the debate is still underway. In recent years, in the effort to clarify the risk of developing dementia or AD, increasing attention has been devoted to the differences between men and women in the causes and manifestations of neurological diseases, as well as to their response to treatment and to outcomes. Through a conceptual analysis we will argue that an emphasis on gender-specific medicine in gene-editing research can contribute to the progress of medicine by introducing a relevant value-driven perspective on health and diseases. This is something we will do on the basis of a gender-specific strategy. In fact, focusing on the effect of sex on dementias and in particular AD may be essential in advancing our understanding, treatment and prevention of these disorders, considering that AD and other dementias disproportionately affect women, and it underlined the relevance of empirical data relating to sex differences and emerging sex-specific findings in dementias in order to assess the scientific approach to these diseases for the improvement of quality of life for both women and men. It may be helpful and suitable to consider how the interventions that modify the genome should include sex and gender as a crucially important variable accounting for the differences between men and women in the causes and manifestations of diseases, as well as in the response to treatment and to outcomes. Of course, gene editing cannot remove biological differences, but its potential harmful effects, on one group relative to another, can be prevented with a research strategy that properly takes them into account with a view to equity between genders.
引用
收藏
相关论文
共 174 条
[1]  
Baggio G(2013)Gender medicine: a task for the third millennium Clin Chem Lab Med 51 713-727
[2]  
Corsini A(2016)CRISPR/Cas9 genome editing—new and old ethical issues arising from a revolutionary technology NanoEthics 10 139-159
[3]  
Floreani A(2015)CRISPR germline engineering—the community speaks Nat Biotechnol 33 478-486
[4]  
Giannini S(2015)Ethics in women’s health: a pathway to gender equity Adv Med Ethics 2 5-251
[5]  
Zagonel V(2016)CRISPR-mediated genome editing and human diseases Genes Dis 3 244-694
[6]  
Bauman M(2017)Benefit-risk assessments at the U.S. Food and Drug Administration: finding the balance J Am Med Assoc 317 693-131
[7]  
Bosley KS(2015)Therapeutic genome editing: prospects and challenges Nat Med 21 121-1436
[8]  
Botchan M(2014)The new frontier of genome engineering with CRISPR–Cas9 Science 346 1077-1787
[9]  
Bredenoord AL(2014)Induced pluripotent stem cells derived from Alzheimer’s disease patients: the promise, the hope and the path ahead J Clin Med 3 1402-586
[10]  
Carroll D(2013)Gender and global health: evidence, policy, and inconvenient truths Lancet 381 1783-70